Charles S.Y. Yang, Taiwan
MagQu Co., Ltd. President OfficeAuthor Of 2 Presentations
LIVE DISCUSSION
DEVELOPMENT OF AN ASSAY OF PLASMA NEUROFILAMENT LIGHT CHAIN UTILIZING IMMUNOMAGNETIC REDUCTION TECHNOLOGY
Abstract
Aims
An assay kit for plasma NFL utilizing immunomagnetic reduction (IMR) was developed. The preclinical properties, such as the standard curve, limit of detection (LoD), and dynamic range, were characterized.
Methods
Thirty-one normal controls (NC), fifty-two patients with Parkinson’s disease (PD) or PD dementia (PDD) and thirty-one patients with Alzheimer’s disease (AD) were enrolled in the study. T-tests and receiver operating characteristic (ROC) curve analysis were performed to investigate the capability for discrimination among the clinical groups according to plasma NFL levels.
Results
The LoD of the NFL assay using the IMR kit was found to be 0.18 fg/ml. The dynamic range of the NFL assay reached 1000 pg/ml. The NC group showed a plasma NFL level of 7.70 ± 4.00 pg/ml, which is significantly lower than that of the PD/PDD (15.85 ± 7.82 pg/ml, p < 0.001) and AD (19.24 ± 8.99 pg/ml, p < 0.001) groups. A significant difference in plasma NFL levels was determined between the PD and AD groups (p < 0.01). The cut-off value of the plasma NFL concentration for differentiating NCs from dementia patients was found to be 12.71 pg/ml, with a clinical sensitivity and specificity of 73.5% and 90.3%, respectively. The AUC was 0.868. Furthermore, the cut-off value of the plasma NFL concentration for discriminating AD from PD/PDD was found to be 18.02 pg/ml, with a clinical sensitivity and specificity of 61.3% and 65.4%, respectively. The AUC was 0.630.
Conclusions
Clear differences in plasma NFL concentrations were observed among NCs and PD and AD patients.
Presenter of 2 Presentations
LIVE DISCUSSION
DEVELOPMENT OF AN ASSAY OF PLASMA NEUROFILAMENT LIGHT CHAIN UTILIZING IMMUNOMAGNETIC REDUCTION TECHNOLOGY
Abstract
Aims
An assay kit for plasma NFL utilizing immunomagnetic reduction (IMR) was developed. The preclinical properties, such as the standard curve, limit of detection (LoD), and dynamic range, were characterized.
Methods
Thirty-one normal controls (NC), fifty-two patients with Parkinson’s disease (PD) or PD dementia (PDD) and thirty-one patients with Alzheimer’s disease (AD) were enrolled in the study. T-tests and receiver operating characteristic (ROC) curve analysis were performed to investigate the capability for discrimination among the clinical groups according to plasma NFL levels.
Results
The LoD of the NFL assay using the IMR kit was found to be 0.18 fg/ml. The dynamic range of the NFL assay reached 1000 pg/ml. The NC group showed a plasma NFL level of 7.70 ± 4.00 pg/ml, which is significantly lower than that of the PD/PDD (15.85 ± 7.82 pg/ml, p < 0.001) and AD (19.24 ± 8.99 pg/ml, p < 0.001) groups. A significant difference in plasma NFL levels was determined between the PD and AD groups (p < 0.01). The cut-off value of the plasma NFL concentration for differentiating NCs from dementia patients was found to be 12.71 pg/ml, with a clinical sensitivity and specificity of 73.5% and 90.3%, respectively. The AUC was 0.868. Furthermore, the cut-off value of the plasma NFL concentration for discriminating AD from PD/PDD was found to be 18.02 pg/ml, with a clinical sensitivity and specificity of 61.3% and 65.4%, respectively. The AUC was 0.630.
Conclusions
Clear differences in plasma NFL concentrations were observed among NCs and PD and AD patients.